Conference Description:

Despite the exciting advancements and new investments into the field, the development of new RNAi therapeutics is plagued by difficulties with extra-hepatic delivery and scale-up of manufacturing production.

in February 2024 the 5th RNAi-Based Therapeutics Summit is returning to Boston with brand-new content and a refreshed pre-conference workshop day which will showcase novel platforms and strategies for targeting beyond the liver to enable the development of RNAi therapeutics to target the undruggable.

This industry dedicated meeting will unite 100+ technical and strategic leaders including Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Transcode Therapeutics, Sirnaomics and OliX Pharmaceuticals to face key bottlenecks within the field through data-driven presentations and interactive, discussion-led sessions to accelerate RNAi therapeutics into the clinic and towards approval.

Tickets: https://go.evvnt.com/2003049-2?pid=154
Time: 8:00 am - 4:00 pm

Prices:
Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4946.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,
Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 4246.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,
Solution Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 6046.00,
Solution Provider - 2 Day Pass (Conference Only): USD 3799.00

Speakers: Frank Slack, Professor, Beth Israel Deaconess Medical Center, Harvard Medical School, Ken Yamada, Assistant Professor, University of Massachusetts Medical School, Jay Kim, Chief Executive Officer, K2B Therapeutics, Marie Lindholm, Senior Vice President, Head of Molecular Design, Silence Therapeutics, Glenn Kazo, Chief Business Officer, ARIZ, Shanthi Ganesh, Director, Discovery Research, Dicerna Pharmaceuticals, Inc., Jim Weterings, Senior Director, Head of Technology Innovation, Sirnaomics, James Ferguson, Chief Medical Officer, Matinas BioPharma, Mano Manoharan, Senior Vice President, Innovation Chemistry and Alnylam Distinguished Scientist, Alnylam Pharmaceuticals, Zdravka Medarova, Founder and Chief Technology Officer, TransCode Therapeutics Inc., Ying Yu, Associate Director, Abbvie, Guy Hermans, Chief Executive Officer, Sapreme Technologies, Iris Grossman, Chief Therapeutics Officer, Eleven Therapeutics, Zhanna Druzina, Senior Director, Aro Biotherapeutics, Richard Welch, Vice President, Chemistry, Manufacturing, and Controls, Sirnaomics, Debasis Patra, Vice President, Head of Chemistry, Manufacturing and Controls, OliX Pharmaceuticals Inc., Benjamin Winkeljann, Group Leader and Chief Executive Officer, RNhale GmbH and LMU Munich, Anja Hog, Chief Development Officer, Heqet Therapeutics, Pooja Dua, Director and Head of Research and Development, OliX Pharmaceuticals, Qian Chen, Scientific Director, NanoDe Therapeutics